Idenix Pharmaceuticals (IDIX)

[DewDiligence]

4Q07 Baraclude sales: $99M, +175% (!) vs 4Q06 and +38% vs 3Q07.

This is a $400M annualized rate.

$70M of the $99M came from outside the US; this number was boosted to some degree by currency.

http://biz.yahoo.com/prnews/080131/nyth043.html

Baraclude has now surpassed Hepsera as the leading HBV drug in worldwide sales. As noted in #msg-26221188, Hepsera sales have plateaued and can be expected to become less and less of a factor in the HBV market, especially when Viread is launched later this year.